Ignacio Melero

Research interests

Publications

• Cancer vaccines: the next immunotherapy frontier

  Nature Cancer · 2022 · 10.1038/s43018-022-00418-6

• Advances in immunotherapy for hepatocellular carcinoma

  Nature Reviews Gastroenterology & Hepatology · 2021 · https://doi.org/10.1038/s41575-021-00438-0

• Intratumoural administration and tumour tissue targeting of cancer immunotherapies

  Nature Reviews Clinical Oncology · 2021 · 10.1038/s41571-021-00507-y

• Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

  Nature Medicine · 2020 · 10.1038/s41591-020-0856-x

• Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

  Frontiers in Immunology · 2020 · 10.3389/fimmu.2020.00951

• CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

  Immunity · 2020 · 10.1016/j.immuni.2020.03.001

• Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

  JAMA Oncology · 2020 · https://doi.org/10.1001/jamaoncol.2020.4564

• Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

  Nature · 2019 · 10.1038/s41586-019-1162-y

• Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

  Nature Medicine · 2019 · 10.1038/s41591-018-0339-5

• Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

  Clinical Cancer Research · 2019 · 10.1158/1078-0432.ccr-18-1538

• Dendritic cells in cancer immunology and immunotherapy

  Nature reviews. Immunology · 2019 · https://doi.org/10.1038/s41577-019-0210-z

• Cytokines in clinical cancer immunotherapy

  British Journal of Cancer · 2018 · https://doi.org/10.1038/s41416-018-0328-y

• Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

  Cell · 2018 · 10.1016/j.cell.2018.11.010

• Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect

  Trends in Immunology · 2018 · 10.1016/j.it.2018.06.001

• Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

  Blood · 2017 · 10.1182/blood-2017-06-741041

• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31046-2

• Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

  Cancer Discovery · 2017 · 10.1158/2159-8290.cd-17-0593

• Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

  Cancer Discovery · 2015 · 10.1158/2159-8290.cd-15-0510

• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  Nature reviews. Cancer · 2015 · 10.1038/nrc3973

• Immunological landscape and immunotherapy of hepatocellular carcinoma

  Nature Reviews Gastroenterology & Hepatology · 2015 · 10.1038/nrgastro.2015.173

• Therapeutic vaccines for cancer: an overview of clinical trials

  Nature Reviews Clinical Oncology · 2014 · 10.1038/nrclinonc.2014.111

• A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

  Journal of Hepatology · 2013 · 10.1016/j.jhep.2013.02.022

• Direct Effects of Type I Interferons on Cells of the Immune System

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-1114

• Immunostimulatory monoclonal antibodies for cancer therapy

  Nature reviews. Cancer · 2007 · 10.1038/nrc2051

• Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

  Nature Medicine · 1997 · 10.1038/nm0697-682

Current projects

No projects listed.